Clicky

CHEMOMAB THERAP. ADR/20(2QV0)

Description: Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.


Keywords: Biotechnology Autoimmune Disease Hepatology Systemic Sclerosis Primary Sclerosing Cholangitis

Home Page: www.chemomab.com

Building 7
Tel Aviv, 6158002
Israel
Phone: 972 77 331 0156


Officers

Name Title
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer, CEO & Executive Director
Ms. Sigal Fattal CPA, M.B.A. Chief Financial Officer
Dr. Matthew B. Frankel M.B.A., M.D. Chief Medical Officer & VP of Drug Development
Barbara Lindheim Consulting Vice President of Investor & Public Relations, Strategic Communications
Mr. Jack Lawler Senior VP of Global Clinical Development Operations

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.7981
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks